Stryker vs Zimmer Biomet
SYK and ZBH side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SYK and ZBH compare
Stryker is the larger company, worth 6.2 times as much as Zimmer Biomet ($121B against $19.5B).
On earnings, Zimmer Biomet is cheaper: it trades at 24.8× trailing earnings, against 33.8× for Stryker.
Zimmer Biomet grew revenue faster over the last twelve months (8.6% versus 7.9% for Stryker).
Stryker keeps more of each dollar of sales as profit, with a net margin of 13.8% compared with 9.5% at Zimmer Biomet.
Both pay dividends: Stryker yields 1.1% and Zimmer Biomet 0.94%.
Stryker scores higher on the StockData Score (18 against 16 for Zimmer Biomet), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SYK | ZBH |
|---|---|---|
| Size and price | ||
| Market cap | $121B | $19.5B |
| Share price | $317.54 | $102.09 |
| Change, 1 year | −12.3% | 13.5% |
| Change, 5 years | 30.4% | −18.7% |
| Beta (5Y) | −0.03 | −0.09 |
| Employees | 56K | 17K |
| StockData Score | ||
| Total score | 18 (better) | 16 |
| Valuation score | 3 | 5 (better) |
| Growth score | 5 (better) | 1 |
| Performance score | 3 | 3 |
| Health score | 4 (better) | 3 |
| Dividend score | 3 | 4 (better) |
| Valuation | ||
| P/E | 33.8× | 24.8× (better) |
| P/S | 4.6× | 2.3× (better) |
| P/B | – | 1.5× |
| EV/EBITDA | 18.8× | 11.5× (better) |
| P/FCF | 26.4× | 12.8× (better) |
| PEG | 3.12 | 0.52 (better) |
| FCF yield | 3.8% | 7.8% (better) |
| Fair value | $338.51 | $124.85 |
| Margin of safety | 6.2% | 18.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 7.9% | 8.6% (better) |
| Revenue growth, 5Y average | 11.8% (better) | 6.1% |
| Net income growth (TTM) | 23.1% (better) | −2.0% |
| EPS growth (TTM) | 23.4% (better) | 0.00% |
| EPS growth, 5Y average | 14.9% | – |
| Profitability | ||
| Gross margin | 65.3% | 69.9% (better) |
| Operating margin | 20.7% (better) | 14.2% |
| Net margin | 13.8% (better) | 9.5% |
| FCF margin | 17.4% | 17.9% (better) |
| Return on equity | – | 6.4% |
| Return on invested capital | – | 5.3% |
| Financial health | ||
| Debt / equity | – | 0.59 |
| Net debt / EBITDA | 1.65 (better) | 3.06 |
| Interest coverage | 9.3× | – |
| Current ratio | 2.18 (better) | 1.69 |
| Altman Z-score | 4.81 (better) | 2.54 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.1% (better) | 0.94% |
| Payout ratio | 36.8% | 23.4% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | – | 3.9% |
| Shareholder yield | 1.1% | 4.8% (better) |
| Ownership | ||
| Held by institutions | 80.9% | 104% |
| Held by insiders | 4.2% | 0.19% |
| Insider net buying, 12 months | −$580M | −$1.6M (better) |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 1.8% | 4.1% |
Go deeper
- SYK stock overview
- SYK income statement
- SYK valuation and score
- ZBH stock overview
- ZBH income statement
- ZBH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.